Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis

Youn H. Kim,H. Miles Prince,Sean Whittaker,Steven M. Horwitz,Madeleine Duvic,Oliver Bechter,Jose A. Sanches,Rudolf Stadler,Julia Scarisbrick,Pietro Quaglino,Pier Luigi Zinzani,Pascal Wolter,Herbert Eradat,Lauren C. Pinter-Brown,Pablo L. Ortiz-Romero,Oleg E. Akilov,Judith Trotman,Kerry Taylor,Michael Weichenthal,Jan Walewski,David Fisher,Marise McNeeley,Alejandro A. Gru,Lisa Brown,M. Corinna Palanca-Wessels,Julie Lisano,Matthew Onsum,Veronica Bunn,Meredith Little,William L. Trepicchio,Reinhard Dummer

EUROPEAN JOURNAL OF CANCER（2021）

引用 30|浏览46
暂无评分
关键词
Antibody-drug conjugate,Brentuximab vedotin,CD30,Cutaneous T-cell lymphoma,Efficacy,Large-cell transformation,Mycosis fungoides,Objective response,Progression-free survival,Safety
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要